Ocular Therapeutix, Inc
OCUL- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001393434
In the last 90 days, Ocular Therapeutix, Inc insiders filed 0 open-market purchases and 5 sales; 262 institutions reported holding it in 13F filings for Q2 2026, worth $2.03B in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Ocular Therapeutix, Inc as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 187
- −7 vs. Q1 2025
- Shares held
- 157.1M
- +19.8M (+14.4%) vs. Q1 2025
- Total value
- $1.45B
- +$447.2M (+44.4%) vs. Q1 2025
- New holders
- 24
- 75 more added
- Sold out
- 31
- 48 more reduced
3 institutions that held it in Q1 2025 haven't filed for Q2 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting OCUL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 262 | $2.03B |
| Q1 2026 | 271 | $1.77B |
| Q4 2025 | 249 | $2.33B |
| Q3 2025 | 216 | $2.20B |
| Q2 2025 | 187 | $1.45B |
| Q1 2025 | 197 | $1.01B |
| Q4 2024 | 180 | $1.14B |
| Q3 2024 | 168 | $1.22B |
| Q2 2024 | 151 | $939.8M |
| Q1 2024 | 147 | $1.12B |
| Q4 2023 | 119 | $328.8M |
| Q3 2023 | 114 | $127.0M |
| Q2 2023 | 135 | $224.2M |
| Q1 2023 | 127 | $213.8M |
| Q4 2022 | 116 | $111.3M |
| Q3 2022 | 130 | $177.6M |
| Q2 2022 | 123 | $178.2M |
| Q1 2022 | 132 | $215.4M |
| Q4 2021 | 140 | $289.1M |
| Q3 2021 | 141 | $445.7M |
| Q2 2021 | 149 | $685.8M |
| Q1 2021 | 154 | $774.9M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Ocular Therapeutix, Inc; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Voloridge Investment Management, LLC | 0 | $0 | 0.00% | −45,437−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −45,054−100.0% | Sold out |
| Caxton Associates LLP | 0 | $0 | 0.00% | −33,821−100.0% | Sold out |
| Nottingham Advisors, Inc. | 0 | $0 | 0.00% | −33,083−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −29,020−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −22,605−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −19,573−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −17,000−100.0% | Sold out |
| Aigen Investment Management, LP | 0 | $0 | 0.00% | −16,164−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −15,306−100.0% | Sold out |
| Principal Financial Group Inc | 0 | $0 | 0.00% | −12,623−100.0% | Sold out |
| Quantinno Capital Management LP | 0 | $0 | 0.00% | −11,079−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −5,238−100.0% | Sold out |
| Signaturefd, LLC | 0 | $0 | 0.00% | −781−100.0% | Sold out |
| Quent Capital, LLC | 0 | $0 | 0.00% | −750−100.0% | Sold out |
| Russell Investments Group, Ltd. | 0 | $0 | 0.00% | −120−100.0% | Sold out |
| Coldstream Capital Management Inc | 0 | $0 | 0.00% | −70−100.0% | Sold out |
| Stephens Consulting, LLC | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Grant/GrossMendelsohn, LLC | – | – | – | – | Not filed |
| Credit Agricole S A | – | – | – | – | Not filed |
| Lindbrook Capital, LLC | – | – | – | – | Not filed |